Thursday, September 21, 2023


“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Novavax to Receive $350 Million for Cancelled COVID Vaccine Orders in Canada

by Rishma Parpia
Novavax COVID vaccines
According to a securities filing with the U.S. Securities and Exchange Commission (SEC) by Novavax Inc. of Gaithersburg, Maryland on June 30, ...

Pfizer CEO Received $24.3 Million in Total Compensation for 2021

by Natasha Hobley
Albert Bourla
Pfizer CEO Albert Bourla, who recently announced that a fourth COVID-19 vaccine dose will be necessary for everyone who has ...

U.S. Consumers Warned About Fraudulent Coronavirus Testing Sites

by Rishma Parpia
coronavirus testing tent
The U.S. Department of Health and Human Services Office of Inspector General has issued a warning to the public about ...

Pfizer Withdraws EUA Application for COVID Shot in India After Regulator Asks for Independent Safety Study

by Rishma Parpia
Pfizer's BNT162b2 biologic
Pfizer, Inc. has withdrawn its emergency use authorization (EUA) application for its experimental BNT162b2 (also known as "Comirnaty") messenger RNA ...

Pharmaceutical Industry Reaping Billions of Dollars in Profits from Coronavirus Tests

by Rishma Parpia
coronavirus test
Since the beginning of the COVID-19 pandemic, public health officials have urged widespread testing for the presence of the SARS-CoV-2 ...

Sales of Pfizer COVID-19 Biologic for 2021-2022 May Near $70 Billion

by TVR Staff
rising profits
Based on better than expected sales of its experimental messenger RNA (mRNA) BNT162b2 COVID-19 biologic, New York-based pharmaceutical company Pfizer, ...

Former Pfizer Employee Whistleblower Alleges Falsified Data in COVID Biologic Trial

by Natasha Hobley
Pfizer whistleblower reveals falsified data
A former testing site researcher in Texas has alleged that Pfizer’s pre-licensure BNT162b2 (also known as "Comirnaty") COVID-19 biologic trials ...

Merck and Pfizer Seek Approval for COVID-19 Antiviral Drugs

by Rishma Parpia
Merck's antiviral drug Molnupiravir
Merck and Pfizer have submitted Emergency Use Authorization (EUA) applications to the U.S. Food and Drug Administration (FDA) to authorize ...

Pfizer Raises Sales Forecast for COVID-19 Biologic to $33.5 Billion in 2021

by Rishma Parpia
revenue growth
Pfizer, Inc. reported that the company sold $7.8 billion worth of their COVID-19 biologic BNT162b2 in the second quarter of ...

In this section

Search in Archive

Search in Site

To search in site, type your keyword and hit enter